New drug combo aims to deepen remission in myeloma transplant patients

NCT ID NCT04680468

Ongoing Disease control Sponsor: University of Pennsylvania Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 11, 2026 · Updated 2 times

Summary

This phase 2 trial is testing whether adding the targeted drug belantamab mafodotin before and after a stem cell transplant can help people with multiple myeloma achieve deeper remission. About 41 participants will receive the drug alongside standard treatments. The main goal is to see how many become free of minimal residual disease (MRD) one year after transplant.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: belantamab mafodotin (an antibody-drug conjugate)
What this could lead to: If successful, this could offer a new way to achieve deeper remission in multiple myeloma patients undergoing stem cell transplant, potentially delaying relapse.
What could go wrong: This is a small, early-phase study (41 people) without a control group, so results may not apply broadly. The drug can cause eye problems and other side effects, and it is not yet proven to improve long-term outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELOMA

Contacts and locations

Locations

University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.